The molecular pathogenesis of pituitary tumors: Implications for clinical management

Minerva Endocrinologica

Volumn 37, Issue 2, 2012, Pages 157-172

  Dworakowska, D ^a,b   Grossman, A B ^c  

^a KING S COLLEGE HOSPITAL   (United Kingdom)

^b MEDICAL UNIVERSITY OF GDANSK   (Poland)

^c UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

Disease management; Pituitary neoplasms; Therapeutics

Indexed keywords

CABERGOLINE; CYCLIC AMP DEPENDENT PROTEIN KINASE 1; DEATH ASSOCIATED PROTEIN KINASE; EVEROLIMUS; FIBROBLAST GROWTH FACTOR RECEPTOR 4; FOLATE RECEPTOR 1; GADD45G PROTEIN; GEFITINIB; KI 67 ANTIGEN; LAPATINIB; MEG3A PROTEIN; MEN1 PROTEIN; OCTREOTIDE; PASIREOTIDE; PROTEIN; PROTEIN P53; PTAG PROTEIN; PTTG PROTEIN; ROSCOVITINE; TEMOZOLOMIDE; UNCLASSIFIED DRUG; ZAC1 PROTEIN;

CANCER CHEMOTHERAPY; CUSHING DISEASE; DRUG MECHANISM; DRUG TREATMENT FAILURE; GENE MUTATION; GLIOBLASTOMA; HUMAN; HYPOPHYSIS ADENOMA; MOLECULAR PATHOLOGY; NONHUMAN; PREDICTIVE VALUE; PROGNOSIS; PROLACTINOMA; PROTEIN EXPRESSION; REVIEW;

ADENOMA; ANTINEOPLASTIC AGENTS; APOPTOSIS; CARCINOMA; CELL TRANSFORMATION, NEOPLASTIC; COMBINED MODALITY THERAPY; DISEASE MANAGEMENT; GENES, NEOPLASM; HUMANS; HYPOPHYSECTOMY; MOLECULAR TARGETED THERAPY; NEOPLASM PROTEINS; NEOPLASTIC SYNDROMES, HEREDITARY; PITUITARY HORMONES; PITUITARY NEOPLASMS; PROGNOSIS; SIGNAL TRANSDUCTION; TUMOR MARKERS, BIOLOGICAL;

EID: 84867290707     PISSN: 03911977     EISSN: 18271634     Source Type: Journal    
DOI: None     Document Type: Review

References (128)

1. Hanson PL, Aylwin SJ, Monson JP, Burrin JM. FSH secretion predominates in vivo and in vitro in patients with non-functioning pituitary adenomas. Eur J Endocrinol 2005;152:363-70. (Pubitemid 40439488)
2. Scheithauer BW, Gaffey TA, Lloyd RV, Sebo TJ, Kovacs KT, Horvath E et al. Pathobiology of pituitary adenomas and carcinomas. Neurosurgery 2006;59:341-53; discussion -53.
3. Levy A. Molecular and trophic mechanisms of tumorigenesis. Endocrinol Metab Clin North Am 2008;37:23-50, vii.
4. Horvath A, Stratakis CA. Clinical and molecular genetics of acromegaly: MEN1, Carney complex, McCune-Albright syndrome, familial acromegaly and genetic defects in sporadic tumors. Rev Endocr Metab Disord 2008;9:1-11.
5. Dworakowska D, Grossman AB. The molecular pathogenesis of corticotroph tumours. Eur J Clin Invest 2012;42:665-76.
6. Dworakowska D, Korbonits M, Aylwin S, McGregor A, Grossman AB. The pathology of pituitary adenomas from a clinical perspective. Frontiers in bioscience (Scholar edition) 2011;3:105-16.
7. Keil MF, Stratakis CA. Pituitary tumors in childhood: update of diagnosis, treatment and molecular genetics. Expert Rev Neurother 2008;8:563-74. (Pubitemid 351551009)
8. Boikos SA, Stratakis CA. Molecular genetics of the cAMP-dependent protein kinase pathway and of sporadic pituitary tumorigenesis. Hum Mol Genet 2007;16 Spec No 1:R80-7. (Pubitemid 47241846)
9. Karhu A, Aaltonen LA. Susceptibility to pituitary neoplasia related to MEN-1, CDKN1B and AIP mutations: an update. Hum Mol Genet 2007;16 Spec No 1:R73-9. (Pubitemid 47241845)
10. Dworakowska D, Grossman AB. The pathophysiology of pituitary adenomas. Best Pract Res Clin Endocrinol Metab 2009;23:525-41.
11. Pellegata NS, Quintanilla-Martinez L, Siggelkow H, Samson E, Bink K, Hofler H et al. Germ-line mutations in p27Kip1 cause a multiple endocrine neoplasia syndrome in rats and humans. Proc Natl Acad Sci U S A 2006;103:15558-63. (Pubitemid 44625631)
12. Vierimaa O, Georgitsi M, Lehtonen R, Vahteristo P, Kokko A, Raitila A et al. Pituitary adenoma predisposition caused by germline mutations in the AIP gene. Science 2006;312:1228-30. (Pubitemid 43801151)
13. Igreja S, Chahal HS, Akker SA, Gueorguiev M, Popovic V, Damjanovic S et al. Assessment of p27 (cyclindependent kinase inhibitor 1B) and AIP (aryl hydrocarbon receptor-interacting protein) genes in MEN1 syndrome patients without any detectable MEN1 gene mutations. Clin Endocrinol (Oxf) 2009;70:259-64.
14. Leontiou CA, Gueorguiev M, van der Spuy J, Quinton R, Lolli F, Hassan S et al. The role of the aryl hydrocarbon receptor-interacting protein gene in familial and sporadic pituitary adenomas. J Clin Endocrinol Metab 2008;93:2390-401. (Pubitemid 351831563)
15. Daly AF, Vanbellinghen JF, Khoo SK, Jaffrain-Rea ML, Naves LA, Guitelman MA et al. Aryl hydrocarbon receptor-interacting protein gene mutations in familial isolated pituitary adenomas: analysis in 73 families. J Clin Endocrinol Metab 2007;92:1891-6. (Pubitemid 46997206)
16. Luccio-Camelo DC, Une KN, Ferreira RE, Khoo SK, Nickolov R, Bronstein MD et al. A meiotic recombination in a new isolated familial somatotropinoma kindred. Eur J Endocrinol 2004;150:643-8. (Pubitemid 38786533)
17. Daly AF, Jaffrain-Rea ML, Ciccarelli A, Valdes-Socin H, Rohmer V, Tamburrano G et al. Clinical characterization of familial isolated pituitary adenomas. J Clin Endocrinol Metab 2006;91:3316-23. (Pubitemid 44402097)
18. Chahal HS CJ, Frohman LA, Grossman AB, Korbonits M. Clinical, genetic and molecular characterisation of patients with familial isolated pituitary adenomas. Trends Endocrinol Metabl 2010;21:419-27.
19. Akintoye SO, Chebli C, Booher S, Feuillan P, Kushner H, Leroith D et al. Characterization of gsp-mediated growth hormone excess in the context of McCune-Albright syndrome. J Clin Endocrinol Metab 2002;87:5104-12. (Pubitemid 35316352)
20. Cuttler L, Jackson JA, Saeed uz-Zafar M, Levitsky LL, Mellinger RC, Frohman LA. Hypersecretion of growth hormone and prolactin in McCune-Albright syndrome. J Clin Endocrinol Metab 1989;68:1148-54. (Pubitemid 19144745)
21. Spada A, Arosio M, Bochicchio D, Bazzoni N, Vallar L, Bassetti M et al. Clinical, biochemical, and morphological correlates in patients bearing growth hormone-secreting pituitary tumors with or without constitutively active adenylyl cyclase. J Clin Endocrinol Metab 1990;71:1421-6. (Pubitemid 120032754)
22. Lania A, Mantovani G, Spada A. Genetics of pituitary tumors: Focus on G-protein mutations. Exp Biol Med (Maywood) 2003;228:1004-17. (Pubitemid 37222168)
23. Burgess JR, Greenaway TM, Shepherd JJ. Expression of the MEN-1 gene in a large kindred with multiple endocrine neoplasia type 1. J Intern Med 1998;243:465-70. (Pubitemid 28312242)
24. Jagannathan J, Dumont AS, Prevedello DM, Lopes B, Oskouian RJ, Jane JA, Jr. et al. Genetics of pituitary adenomas: current theories and future implications. Neurosurg Focus 2005;19.E4.
25. Farrell WE, Simpson DJ, Bicknell J, Magnay JL, Kyrodimou E, Thakker RV et al. Sequence analysis and transcript expression of the MEN1 gene in sporadic pituitary tumours. Br J Cancer 1999;80:44-50. (Pubitemid 29210086)
26. Poncin J, Stevenaert A, Beckers A. Somatic MEN1 gene mutation does not contribute significantly to sporadic pituitary tumorigenesis. Eur J Endocrinol 1999;140:573-6. (Pubitemid 29314720)
27. Trouillas J, Labat-Moleur F, Sturm N, Kujas M, Heymann MF, Figarella-Branger D et al. Pituitary tumors and hyperplasia in multiple endocrine neoplasia type 1 syndrome (MEN1): a case-control study in a series of 77 patients versus 2509 non-MEN1 patients. Am J Surg Pathol 2008;32:534-43. (Pubitemid 351458295)
28. Dahia PL, Aguiar RC, Honegger J, Fahlbush R, Jordan S, Lowe DG et al. Mutation and expression analysis of the p27/kip1 gene in corticotrophin- secreting tumours. Oncogene 1998;16:69-76. (Pubitemid 28043509)
29. Hai N, Aoki N, Shimatsu A, Mori T, Kosugi S. Clinical features of multiple endocrine neoplasia type 1 (MEN1) phenocopy without germline MEN1 gene mutations: analysis of 20 Japanese sporadic cases with MEN1. Clin Endocrinol (Oxf) 2000;52:509-18. (Pubitemid 30249820)
30. Georgitsi M, Raitila A, Karhu A, van der Luijt RB, Aalfs CM, Sane T et al. Germline CDKN1B/p27Kip1 mutation in multiple endocrine neoplasia. J Clin Endocrinol Metab 2007;92:3321-5. (Pubitemid 47236408)
31. Lloyd RV, Jin L, Qian X, Kulig E. Aberrant p27kip1 expression in endocrine and other tumors. Am J Pathol 1997;150:401-7. (Pubitemid 27073769)
32. Lidhar K, Korbonits M, Jordan S, Khalimova Z, Kaltsas G, Lu X et al. Low expression of the cell cycle inhibitor p27Kip1 in normal corticotroph cells, corticotroph tumors, and malignant pituitary tumors. J Clin Endocrinol Metab 1999;84:3823-30. (Pubitemid 30645248)
33. Milne TA, Hughes CM, Lloyd R, Yang Z, Rozenblatt-Rosen O, Dou Y et al. Menin and MLL cooperatively regulate expression of cyclin-dependent kinase inhibitors. Proc Natl Acad Sci U S A 2005;102:749-54. (Pubitemid 40282737)
34. Drosten M, Hilken G, Bockmann M, Rodicker F, Mise N, Cranston AN et al. Role of MEN2A-derived RET in maintenance and proliferation of medullary thyroid carcinoma. J Natl Cancer Inst 2004;96:1231-9. (Pubitemid 39232714)
35. Kolluri SK, Weiss C, Koff A, Gottlicher M. p27(Kip1) induction and inhibition of proliferation by the intracellular Ah receptor in developing thymus and hepatoma cells. Genes Dev 1999;13:1742-53. (Pubitemid 29325878)
36. Kirschner LS, Carney JA, Pack SD, Taymans SE, Giatzakis C, Cho YS et al. Mutations of the gene encoding the protein kinase A type I-alpha regulatory subunit in patients with the Carney complex. Nat Genet 2000;26:89-92.
37. Bossis I, Voutetakis A, Matyakhina L, Pack S, Abu-Asab M, Bourdeau I et al. A pleiomorphic GH pituitary adenoma from a Carney complex patient displays universal allelic loss at the protein kinase A regulatory subunit 1A (PRKARIA) locus. J Med Genet 2004;41:596-600. (Pubitemid 39061265)
38. Yin Z, Williams-Simons L, Parlow AF, Asa S, Kirschner LS. Pituitary-specific knockout of the Carney complex gene Prkar1a leads to pituitary tumorigenesis. Mol Endocrinol 2008;22:380-7. (Pubitemid 351185937)
39. Kaltsas GA, Kola B, Borboli N, Morris DG, Gueorguiev M, Swords FM et al. Sequence analysis of the PRKAR1A gene in sporadic somatotroph and other pituitary tumours. Clin Endocrinol (Oxf) 2002;57:443-8. (Pubitemid 35216295)
40. Sandrini F, Kirschner LS, Bei T, Farmakidis C, Yasufuku-Takano J, Takano K et al. PRKAR1A, one of the Carney complex genes, and its locus (17q22-24) are rarely altered in pituitary tumours outside the Carney complex. J Med Genet 2002;39:e78.
41. Georgitsi M, Raitila A, Karhu A, Tuppurainen K, Makinen MJ, Vierimaa O et al. Molecular diagnosis of pituitary adenoma predisposition caused by aryl hydrocarbon receptor-interacting protein gene mutations. Proc Natl Acad Sci U S A 2007;104:4101-5. (Pubitemid 47181585)
42. Beckers A, Daly AF. The clinical, pathological, and genetic features of familial isolated pituitary adenomas. Eur J Endocrinol 2007;157:371-82. (Pubitemid 350018439)
43. Marlowe JL, Puga A. Aryl hydrocarbon receptor, cell cycle regulation, toxicity, and tumorigenesis. J Cell Biochem 2005;96:1174-84. (Pubitemid 41681860)
44. Tichomirowa MA, Barlier A, Daly AF, Jaffrain-Rea ML, Ronchi C, Yaneva M et al. High prevalence of AIP gene mutations following focused screening in young patients with sporadic pituitary macroadenomas. Eur J Endocrinol 2011;165:509-15.
45. Asa SL, Ezzat S. The pathogenesis of pituitary tumours. Nat Rev Cancer 2002;2:836-49. (Pubitemid 37328902)
46. Karga HJ, Alexander JM, Hedley-Whyte ET, Klibanski A, Jameson JL. Ras mutations in human pituitary tumors. J Clin Endocrinol Metab 1992;74:914-9.
47. Herman V, Drazin NZ, Gonsky R, Melmed S. Molecular screening of pituitary adenomas for gene mutations and rearrangements. J Clin Endocrinol Metab 1993;77:50-5. (Pubitemid 23206775)
48. Boggild MD, Jenkinson S, Pistorello M, Boscaro M, Scanarini M, McTernan P et al. Molecular genetic studies of sporadic pituitary tumors. J Clin Endocrinol Metab 1994;78:387-92. (Pubitemid 24061758)
49. Cryns VL, Alexander JM, Klibanski A, Arnold A. The retinoblastoma gene in human pituitary tumors. J Clin Endocrinol Metab 1993;77:644-6. (Pubitemid 23298641)
50. Pei L, Melmed S, Scheithauer B, Kovacs K, Benedict WF, Prager D. Frequent loss of heterozygosity at the retinoblastoma susceptibility gene (RB) locus in aggressive pituitary tumors: evidence for a chromosome 13 tumor suppressor gene other than RB. Cancer Res 1995;55:1613-6.
51. Tanizaki Y, Jin L, Scheithauer BW, Kovacs K, Roncaroli F, Lloyd RV. P53 gene mutations in pituitary carcinomas. Endocr Pathol 2007;18:217-22.
52. Pei L, Melmed S. Isolation and characterization of a pituitary tumor-transforming gene (PTTG). Mol Endocrinol 1997;11:433-41. (Pubitemid 27147011)
53. Salehi F, Kovacs K, Scheithauer BW, Lloyd RV, Cusimano M. Pituitary tumor-transforming gene in endocrine and other neoplasms: a review and update. Endocr Relat Cancer 2008;15:721-43.
54. Bharadwaj R, Yu H. The spindle checkpoint, aneuploidy, and cancer. Oncogene 2004;23:2016-27. (Pubitemid 38496731)
55. Zhang X, Horwitz GA, Heaney AP, Nakashima M, Prezant TR, Bronstein MD et al. Pituitary tumor transforming gene (PTTG) expression in pituitary adenomas. J Clin Endocrinol Metab 1999;84:761-7. (Pubitemid 29075718)
56. Wang Z, Melmed S. Pituitary tumor transforming gene (PTTG) transforming and transactivation activity. J Biol Chem 2000;275:7459-61. (Pubitemid 30159638)
57. Chamaon K, Kirches E, Kanakis D, Braeuninger S, Dietzmann K, Mawrin C. Regulation of the pituitary tumor transforming gene by insulin-like-growth factor-I and insulin differs between malignant and non-neoplastic astrocytes. Biochem Biophys Res Commun 2005;331:86-92. (Pubitemid 40545146)
58. Dworakowska D, Wlodek E, Leontiou CA, Igreja S, Cakir M, Teng M et al. Activation of RAF/MEK/ERK and PI3K/AKT/mTOR pathways in pituitary adenomas and their effects on downstream effectors. Endocr Relat Cancer 2009;16:1329-38.
59. Rodriguez-Viciana P, Warne PH, Khwaja A, Marte BM, Pappin D, Das P et al. Role of phosphoinositide 3-OH kinase in cell transformation and control of the actin cytoskeleton by Ras. Cell 1997;89:457-67. (Pubitemid 27220890)
60. Kauffmann-Zeh A, Rodriguez-Viciana P, Ulrich E, Gilbert C, Coffer P, Downward J et al. Suppression of c-Myc-induced apoptosis by Ras signalling through PI(3)K and PKB. Nature 1997;385:544-8. (Pubitemid 27074674)
61. Volarevic S, Thomas G. Role of S6 phosphorylation and S6 kinase in cell growth. Prog Nucleic Acid Res Mol Biol 2001;65:101-27.
62. Lin Y, Jiang X, Shen Y, Li M, Ma H, Xing M et al. Frequent mutations and amplifications of the PIK-3CA gene in pituitary tumors. Endocr Relat Cancer 2009;16:301-10.
63. Musat M, Korbonits M, Kola B, Borboli N, Hanson MR, Nanzer AM et al. Enhanced protein kinase B/Akt signalling in pituitary tumours. Endocr Relat Cancer 2005,12:423-33. (Pubitemid 40896456)
64. Adjei AA, Hidalgo M. Intracellular signal transduction pathway proteins as targets for cancer therapy. J Clin Oncol 2005;23:5386-403. (Pubitemid 46206992)
65. Haystead TA, Dent P, Wu J, Haystead CM, Sturgill TW. Ordered phosphorylation of p42mapk by MAP kinase kinase. FEBS Lett 1992;306:17-22.
66. Terada Y, Nakashima O, Inoshita S, Kuwahara M, Sasaki S, Marumo F. Mitogen-activated protein kinase cascade and transcription factors: the opposite role of MKK3/6-P38K and MKK1-MAPK. Nephrol Dial Transplant 1999;14 Suppl 1:45-7. (Pubitemid 29041837)
67. Terada Y, Inoshita S, Nakashima O, Kuwahara M, Sasaki S, Marumo F. Regulation of cyclin D1 expression and cell cycle progression by mitogen-activated protein kinase cascade. Kidney Im 1999;56:1258-61. (Pubitemid 29451224)
68. Guan KL. The mitogen activated protein kinase signal transduction pathway: from the cell surface to the nucleus. Cell Signal 1994;6:581-9.
69. Joneson T, Bar-Sagi D. Ras effectors and their role in mitogenesis and oncogenesis. J Mol Med 1997;75:587-93. (Pubitemid 27373601)
70. Gueorguiev M, Grossman AB. Pituitary gland and beta-catenin signaling: from ontogeny to oncogenesis. Pituitary 2009;12:245-55.
71. Ewing I, Pedder-Smith S, Franchi G, Ruscica M, Emery M, Vax V et al. A mutation and expression analysis of the oncogene BRAF in pituitary adenomas. Clin Endocrinol (Oxf) 2007;66:348-52. (Pubitemid 46239291)
72. Hibberts NA, Simpson DJ, Bicknell JE, Broome JC, Hoban PR, Clayton RN et al. Analysis of cyclin D1 (CCND1) allelic imbalance and overexpression in sporadic human pituitary tumors. Clin Cancer Res 1999;5:2133-9. (Pubitemid 29399269)
73. Jordan S, Lidhar K, Korbonits M, Lowe DG, Grossman AB. Cyclin D and cyclin E expression in normal and adenomatous pituitary. Eur J Endocrinol 2000;143:R1-6. (Pubitemid 30482213)
74. McCubrey JA, Steelman LS, Abrams SL, Lee JT, Chang F, Bertrand FE et al. Roles of the RAF/MEK/ERK and PI3K/PTEN/AKT pathways in malignant transformation and drug resistance. Adv Enzyme Regul 2006;46:249-79. (Pubitemid 44301348)
75. Cakir M, Grossman AB. Targeting MAPK (Ras/ERK) and PI3K/Akt pathways in pituitary tumorigenesis. Expert opinion on therapeutic targets 2009;13:1121-34.
76. Butz H, Liko I, Czirjak S, Igaz P, Korbonits M, Racz K et al. MicroRNA profile indicates downregulation of the TGFbeta pathway in sporadic non-functioning pituitary adenomas. Pituitary 2011;14:112-24.
77. Gejman R, Swearingen B, Hedley-Whyte ET. Role of Ki-67 proliferation index and p53 expression in predicting progression of pituitary adenomas. Human pathology 2008;39:758-66. (Pubitemid 351601606)
78. Noh TW, Jeong HJ, Lee MK, Kim TS, Kim SH, Lee EJ. Predicting recurrence of nonfunctioning pituitary adenomas. J Clin Endocrinol Metab 2009;94:4406-13.
79. Ogawa Y, Ikeda H, Tominaga T. Clinicopathological study of prognostic factors in patients with pituitary adenomas and Ki-67 labeling index of more than 3%. J Endocrinol Invest 2009;32:581-4.
80. Chacko G, Chacko AG, Kovacs K, Scheithauer BW, Mani S, Muliyil JP et al. The clinical significance of MIB-1 labeling index in pituitary adenomas. Pituitary 2010;13:337-44.
81. de Aguiar PH, Aires R, Laws ER, Isolan GR, Logullo A, Patil C et al. Labeling index in pituitary adenomas evaluated by means of MIB-1: is there a prognostic role? A critical review. Neurological research 2010;32:1060-71.
82. Grossman AB. The molecular biology of pituitary tumors: a personal perspective. Pituitary 2009;12:265-70.
83. Lu C, Willingham MC, Furuya F, Cheng SY. Activation of phosphatidylinositol 3-kinase signaling promotes aberrant pituitary growth in a mouse model of thyroid-stimulating hormone-secreting pituitary tumors. Endocrinology 2008;149:3339-45. (Pubitemid 351919619)
84. An JJ, Cho SR, Jeong DW, Park KW, Ahn YS, Baik JH. Anti-proliferative effects and cell death mediated by two isoforms of dopamine D2 receptors in pituitary tumor cells. Molecular and cellular endocrinology 2003;206:49-62. (Pubitemid 37011252)
85. Fougner SL, Bollerslev J, Latif F, Hald JK, Lund T, Ramm-Pettersen J et al. Low levels of raf kinase inhibitory protein in growth hormone-secreting pituitary adenomas correlate with poor response to octreotide treatment. J Clin Endocrinol Metab 2008;93:1211-6. (Pubitemid 351519712)
86. Tanase CP, Neagu M, Albulescu R. Key signaling molecules in pituitary tumors. Expert review of molecular diagnostics 2009;9:859-77.
87. Bertherat J, Chanson P, Montminy M. The cyclic adenosine 3′,5′-monophosphate-responsive factor CREB is constitutively activated in human somatotroph adenomas. Mol Endocrinol 1995;9:777-83.
88. Lee EJ, Duan WR, Kotlar T, Jameson JL. Restoration of growth hormone-releasing hormone (GHRH) responsiveness in pituitary GH3 cells by adenovirus-directed expression of the human GHRH receptor. Endocrinology 2001;142:414-20. (Pubitemid 32183703)
89. Theodoropoulou M, Zhang J, Laupheimer S, Paez-Pereda M, Erneux C, Florio T et al. Octreotide, a somatostatin analogue, mediates its antiproliferative action in pituitary tumor cells by altering phosphatidylinositol 3-kinase signaling and inducing Zac1 expression. Cancer Res 2006;66:1576-82. (Pubitemid 43259940)
90. Theodoropoulou M, Stalla GK, Spengler D. ZAC1 target genes and pituitary tumorigenesis. Molecular and cellular endocrinology 2010;326:60-5.
91. Pagotto U, Arzberger T, Theodoropoulou M, Grubler Y, Pantaloni C, Saeger W et al. The expression of the antiproliferative gene ZAC is lost or highly reduced in nonfunctioning pituitary adenomas. Cancer Res 2000;60:6794-9. (Pubitemid 32059140)
92. Chahal HS TG, Leontiou CA, Alband N, Fowkes RC, Tahir A, Igreja SC, Chappie JP, Jordan S, Lupp A, Schulz S, Ansorge O, Karavitaki N, Carlsen E, Wass JAH, Grossman AB, Korbonits M. Somatostatin analogues modulate AIP in somatotroph adenomas - the role of the ZAC1 pathway. J Clin Endocrinol Metab 2012; in press.
93. Fougner SL, Lekva T, Borota OC, Hald JK, Bollerslev J, Berg JP. The Expression of E-Cadherin in Somatotroph Pituitary Adenomas Is Related to Tumor Size, Invasiveness, and Somatostatin Analog Response. J Clin Endocrinol Metab 2010;95:2334-42.
94. Machado AL, Nomikos P, Kiesewetter F, Fahlbusch R, Buchfelder M. DNA-flow cytometry of 207 pituitary adenomas: ploidy, proliferation, and prognosis. J Endocrinol Invest 2005;28:795-801. (Pubitemid 43162833)
95. Filippella M, Galland F, Kujas M, Young J, Faggiano A, Lombardi G et al. Pituitary tumour transforming gene (PTTG) expression correlates with the proliferative activity and recurrence status of pituitary adenomas: a clinical and immunohistochemical study. Clin Endocrinol (Oxf) 2006;65:536-43. (Pubitemid 44414280)
96. McCabe CJ, Boelaert K, Tannahill LA, Heaney AP, Stratford AL, Khaira JS et al. Vascular endothelial growth factor, its receptor KDR/Flk-1, and pituitary tumor transforming gene in pituitary tumors. J Clin Endocrinol Metab 2002;87:4238-44.
97. Minematsu T, Suzuki M, Sanno N, Takekoshi S, Teramoto A, Osamura RY. PTTG overexpression is correlated with angiogenesis in human pituitary adenomas. Endocr Pathol 2006;17:143-53. (Pubitemid 44965903)
98. Powers CJ, McLeskey SW, Wellstein A. Fibroblast growth factors, their receptors and signaling. Endocr Relat Cancer 2000;7:165-97.
99. Givol D, Yayon A. Complexity of FGF receptors: genetic basis for structural diversity and functional specificity. FASEB J 1992;6:3362-9. (Pubitemid 23007101)
100. Ezzat S, Smyth HS, Ramyar L, Asa SL. Heterogenous in vivo and in vitro expression of basic fibroblast growth factor by human pituitary adenomas. J Clin Endocrinol Metab 1995;80:878-84.
101. Qian ZR, Sano T, Asa SL, Yamada S, Horiguchi H, Tashiro T et al. Cytoplasmic expression of fibroblast growth factor receptor-4 in human pituitary adenomas: relation to tumor type, size, proliferation, and invasiveness. J Clin Endocrinol Metab 2004;89:1904-11. (Pubitemid 38507952)
102. Qu X, Yang W, Jiang M, Han T, Han L, Qu Y et al. CD147 expression in pituitary adenomas and its significance for clinical outcome. Human pathology 2010;41:1165-71.
103. Raverot G, Wierinckx A, Dantony E, Auger C, Chapas G, Villeneuve L et al. Prognostic factors in prolactin pituitary tumors: clinical, histological, and molecular data from a series of 94 patients with a long postoperative follow-up. J Clin Endocrinol Metab 2010;95:1708-16.
104. Shan B, Gerez J, Haedo M, Fuertes M, Theodoropoulou M, Buchfelder M et al. RSUME is implicated in HIF-1-induced VEGF-A production in pituitary tumour cells. Endocr Relat Cancer 2012;19:13-27.
105. Cooper O, Vlotides G, Fukuoka H, Greene MI, Melmed S. Expression and function of ErbB receptors and ligands in the pituitary. Endocr Relat Cancer 2011;18:R197-211.
106. Fukuoka H, Cooper O, Ben-Shlomo A, Mamelak A, Ren SG, Bruyette D et al. EGFR as a therapeutic target for human, canine, and mouse ACTH-secreting pituitary adenomas. J Clin Invest 2011;121:4712-21.
107. Vlotides G, Siegel E, Donangelo I, Gutman S, Ren SG, Melmed S. Rat prolactinoma cell growth regulation by epidermal growth factor receptor ligands. Cancer Res 2008;68:6377-86.
108. Vlotides G, Cooper O, Chen YH, Ren SG, Greenman Y, Melmed S. Heregulin regulates prolactinoma gene expression. Cancer Res 2009;69:4209-16.
109. Fukuoka H, Cooper O, Mizutani J, Tong Y, Ren SG, Bannykh S et al. HER2/ErbB2 receptor signaling in rat and human prolactinoma cells: strategy for targeted prolactinoma therapy. Mol Endocrinol 2011;25.92-103.
110. Raica M, Coculescu M, Cimpean AM, Ribatti D. Endocrine gland derived-VEGF is down-regulated in human pituitary adenoma. Anticancer research 2010;30:3981-6.
111. Cristina C, Perez-Millan MI, Luque G, Dulce RA, Sevlever G, Berner SI et al. VEGF and CD31 association in pituitary adenomas. Endocr Pathol 2010;21:154-60.
112. Kurosaki M, Saegert W, Abe T, Ludecke DK. Expression of vascular endothelial growth factor in growth hormone-secreting pituitary adenomas: special reference to the octreotide treatment. Neurological research 2008;30:518-22. (Pubitemid 352008712)
113. Yarman S, Kurtulmus N, Canbolat A, Bayindir C, Bilgic B, Ince N. Expression of Ki-67, p53 and vascular endothelial growth factor (VEGF) concomitantly in growth hormone-secreting pituitary adenomas; which one has a role in tumor behavior ? Neuro endocrinology letters 2010;31:823-8.
114. Luque GM, Perez-Millan MI, Ornstein AM, Cristina C, Becu-Villalobos D. Inhibitory effects of antivascular endothelial growth factor strategies in experimental dopamine-resistant prolactinomas. The Journal of pharmacology and experimental therapeutics 2011;337:766-74.
115. Korsisaari N, Ross J, Wu X, Kowanetz M, Pal N, Hall L et al. Blocking vascular endothelial growth factor-A inhibits the growth of pituitary adenomas and lowers serum prolactin level in a mouse model of multiple endocrine neoplasia type 1. Clin Cancer Res 2008;14:249-58. (Pubitemid 351378002)
116. Gagliano T, Filieri C, Minoia M, Buratto M, Tagliati F, Ambrosio MR et al. Cabergoline reduces cell viability in non functioning pituitary adenomas by inhibiting vascular endothelial growth factor secretion. Pituitary 2012 [Epub ahead of print].
117. Liu NA, Jiang H, Ben-Shlomo A, Wawrowsky K, Fan XM, Lin S et al. Targeting zebrafish and murine pituitary corticotroph tumors with a cyclin-dependent kinase (CDK) inhibitor. Proc Natl Acad Sci U S A 2011;108:8414-9.
118. McCormack AI, Wass JA, Grossman AB. Aggressive pituitary tumours: the role of temozolomide and the assessment of MGMT status. Eur J Clin Invest 2011;41:1133-48.
119. Annamalai AK, Dean AF, Kandasamy N, Kovacs K, Burton H, Halsall DJ et al. Temozolomide responsiveness in aggressive corticotroph tumours: a case report and review of the literature. Pituitary 2011 [Epub ahead of print].
120. Zuhur SS, Tanik C, Karaman O, Velet S, Cil E, Ozturk FY et al. MGMT immunoexpression in growth hormone-secreting pituitary adenomas and its correlation with Ki-67 labeling index and cytokeratin distribution pattern. Endocrine 2011;40:222-7.
121. Pedroncelli AM. Medical treatment of Cushing's disease: somatostatin analogues and pasireotide. Neuroendocrinology 2010;92(Suppl 1):120-4.
122. Zatelli MC, Piccin D, Vignali C, Tagliati F, Ambrosio MR, Bondanelli M et al. Pasireotide, a multiple somatostatin receptor subtypes ligand, reduces cell viability in non-functioning pituitary adenomas by inhibiting vascular endothelial growth factor secretion. Endocr Relat Cancer 2007;14:91-102. (Pubitemid 47521725)
123. Zatelli MC, Minoia M, Filieri C, Tagliati F, Buratto M, Ambrosio MR et al. Effect of everolimus on cell viability in nonfunctioning pituitary adenomas. J Clin Endocrinol Metab 2010;95:968-76.
124. Jouanneau E, Wierinckx A, Ducray F, Favrel V, Borson-Chazot F, Honnorat J et al. New targeted therapies in pituitary carcinoma resistant to temozolomide. Pituitary 2012;15:37-43.
125. Evans CO, Yao C, Laborde D, Oyesiku NM. Folate receptor expression in pituitary adenomas cellular and molecular analysis. Vitamins and hormones 2008;79:235-66.
126. Galt JR, Halkar RK, Evans CO, Osman NA, LaBorde D, Fox TH et al. In vivo assay of folate receptors in nonfunctional pituitary adenomas with 99mTc-folate SPECT/CT. J Nucl Med 2010;51:1716-23.
127. Baldari S, Ferrau F, Alafaci C, Herberg A, Granata F, Militano V et al. First demonstration of the effectiveness of peptide receptor radionuclide therapy (PRRT) with 111In-DTPA-octreotide in a giant PRL-secreting pituitary adenoma resistant to conventional treatment. Pituitary 2012;Epub ahead of print.
128. de Jong M, Breeman WA, Bernard BF, Bakker WH, Schaar M, van Gameren A et al. [177Lu-DOTA(0),Tyr3] octreotate for somatostatin receptor-targeted radionuclide therapy. International journal of cancer 2001;92:628-33. (Pubitemid 32385702)